CN117941777A - Application of mannooligosaccharide in preparation of feed for reducing intestinal inflammation of freshwater fish caused by high-fat feed - Google Patents
Application of mannooligosaccharide in preparation of feed for reducing intestinal inflammation of freshwater fish caused by high-fat feed Download PDFInfo
- Publication number
- CN117941777A CN117941777A CN202410277618.6A CN202410277618A CN117941777A CN 117941777 A CN117941777 A CN 117941777A CN 202410277618 A CN202410277618 A CN 202410277618A CN 117941777 A CN117941777 A CN 117941777A
- Authority
- CN
- China
- Prior art keywords
- parts
- feed
- mannooligosaccharide
- vitamin
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000251468 Actinopterygii Species 0.000 title claims abstract description 68
- 239000013505 freshwater Substances 0.000 title claims abstract description 47
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 46
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 34
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title description 4
- 241000264847 Siniperca chuatsi Species 0.000 claims description 13
- 235000021323 fish oil Nutrition 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 229930003270 Vitamin B Natural products 0.000 claims description 8
- 235000019156 vitamin B Nutrition 0.000 claims description 8
- 239000011720 vitamin B Substances 0.000 claims description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 229920002261 Corn starch Polymers 0.000 claims description 4
- 235000019733 Fish meal Nutrition 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 239000004467 fishmeal Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 108010068370 Glutens Proteins 0.000 claims description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 240000008042 Zea mays Species 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 3
- 229910021536 Zeolite Inorganic materials 0.000 claims description 3
- 229940071097 ascorbyl phosphate Drugs 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- 229960002079 calcium pantothenate Drugs 0.000 claims description 3
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 claims description 3
- 235000005822 corn Nutrition 0.000 claims description 3
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 235000021312 gluten Nutrition 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- XBDUTCVQJHJTQZ-UHFFFAOYSA-L iron(2+) sulfate monohydrate Chemical compound O.[Fe+2].[O-]S([O-])(=O)=O XBDUTCVQJHJTQZ-UHFFFAOYSA-L 0.000 claims description 3
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 claims description 3
- 235000012054 meals Nutrition 0.000 claims description 3
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims description 3
- 239000001230 potassium iodate Substances 0.000 claims description 3
- 235000006666 potassium iodate Nutrition 0.000 claims description 3
- 229940093930 potassium iodate Drugs 0.000 claims description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
- 239000011781 sodium selenite Substances 0.000 claims description 3
- 235000015921 sodium selenite Nutrition 0.000 claims description 3
- 229960001471 sodium selenite Drugs 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 239000010457 zeolite Substances 0.000 claims description 3
- 229940118149 zinc sulfate monohydrate Drugs 0.000 claims description 3
- RNZCSKGULNFAMC-UHFFFAOYSA-L zinc;hydrogen sulfate;hydroxide Chemical compound O.[Zn+2].[O-]S([O-])(=O)=O RNZCSKGULNFAMC-UHFFFAOYSA-L 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- 241001597062 Channa argus Species 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- 229930003448 Vitamin K Natural products 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 claims description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019168 vitamin K Nutrition 0.000 claims description 2
- 239000011712 vitamin K Substances 0.000 claims description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 229940046010 vitamin k Drugs 0.000 claims description 2
- 235000009200 high fat diet Nutrition 0.000 claims 3
- 241000218652 Larix Species 0.000 claims 1
- 235000005590 Larix decidua Nutrition 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 51
- 102000004127 Cytokines Human genes 0.000 abstract description 32
- 108090000695 Cytokines Proteins 0.000 abstract description 32
- 108090000623 proteins and genes Proteins 0.000 abstract description 19
- 230000000770 proinflammatory effect Effects 0.000 abstract description 17
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 14
- 210000005027 intestinal barrier Anatomy 0.000 abstract description 13
- 230000007358 intestinal barrier function Effects 0.000 abstract description 13
- 230000001105 regulatory effect Effects 0.000 abstract description 13
- 238000009360 aquaculture Methods 0.000 abstract description 8
- 244000144974 aquaculture Species 0.000 abstract description 8
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 10
- 238000011160 research Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 108090000304 Occludin Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 208000018191 liver inflammation Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- 108050009302 Claudin Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 241001125889 Micropterus salmoides Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000003940 Occludin Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000404975 Synchiropus splendidus Species 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 241001417978 Channidae Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 102000002029 Claudin Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000549435 Pria Species 0.000 description 1
- 229910018143 SeO3 Inorganic materials 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 230000004887 epithelial permeability Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008946 inflammatory intestinal reaction Effects 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- -1 mannose oligosaccharide Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000018648 unbalanced nutrition Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
- A23K10/22—Animal feeding-stuffs from material of animal origin from fish
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/28—Silicates, e.g. perlites, zeolites or bentonites
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
- Y02A40/818—Alternative feeds for fish, e.g. in aquacultures
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Insects & Arthropods (AREA)
- Birds (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Feed For Specific Animals (AREA)
Abstract
The invention discloses an application of mannooligosaccharide in preparing feed for relieving intestinal inflammation of freshwater fish caused by high-fat feed, and belongs to the technical field of aquaculture. The invention is verified by the practice that: the invention prepares the high-fat feed containing the mannooligosaccharide by adding the chitosan oligosaccharide into the high-fat feed and optimizing and improving various components and dosage, and the improved high-fat feed reduces the intestinal inflammation of the freshwater fish by regulating the expression of the pro-inflammatory cytokines, the anti-inflammatory cytokines and the related genes of the intestinal barrier. The invention provides a theoretical basis for reducing the intestinal inflammation of freshwater fish caused by high-fat feed and a novel high-fat feed formula.
Description
Technical Field
The invention relates to the technical field of aquaculture, in particular to application of mannooligosaccharide in preparation of feed for relieving intestinal inflammation of freshwater fish caused by high-fat feed.
Background
Fat is an important energy substance in living body, and has various functions of providing energy for living body, providing necessary fatty acid, maintaining structure and function of biological film, and providing carrier of fat-soluble vitamin in body. In aquatic feed, the proper fat level and balanced fatty acid composition can promote the growth, development, reproduction and other life processes of fish. The feed fat can be used for saving protein, and under the current realistic background of shortage of feed protein sources and high price, the high-fat feed is widely used in aquatic feeds to save feed protein and reduce nitrogen and phosphorus emission. However, long-term use of high-fat feeds has many adverse effects on aquatic animals, such as excessive deposition of liver fat of fish, metabolic disturbance, reduced immunity, and induction of inflammatory reactions and tissue damage in intestinal tracts, which have hampered healthy development of aquaculture industry. The intestinal tract is an important digestive and immune organ of fish. The intestinal tract plays a vital role in fish growth and health by selectively absorbing nutrients and secreting a range of mucous and cytokines. However, conditions of unbalanced nutrition of feeds such as high-fat feeds affect intestinal health of fish to various degrees, and induce intestinal epithelial permeability increase, intestinal epithelial barrier function loss, contact of intestinal lumen antigen microorganisms with lamina propria immune cells, and the like, namely, the occurrence of intestinal inflammatory reaction. Solving the problem of high-fat induced fish intestinal inflammation is a bottleneck which needs to be broken through in the current aquaculture.
Prebiotics are non-digestible ingredients that are selectively utilized by host microorganisms and have a beneficial effect on host health. The research in mammals shows that the prebiotics added into the diet has the functions of maintaining the balance of intestinal microbiota and reducing liver sugar and lipid metabolism disturbance related to the non-alcoholic fatty liver. In aquaculture, prebiotics are mainly used to improve aquatic animal growth performance, feed utilization, intestinal health, and to increase their ability to cope with pathogens and stresses. Mannooligosaccharides (mannan oligosaccharides, MOS) are a common prebiotic in aquaculture. Current research focuses on the regulation of growth, immunity and intermediary metabolic processes in aquatic animals by MOS. However, it is unclear whether the use of MOS in aquatic animals can alleviate high-fat-induced intestinal inflammation in fish. In view of this, it is necessary to design a feed capable of reducing the intestinal inflammation of freshwater fish caused by a high-fat feed, so as to solve the above-mentioned problems.
Disclosure of Invention
The invention aims to provide an application of mannooligosaccharide in preparing a feed for relieving intestinal inflammation of freshwater fish caused by high-fat feed, so as to solve the problems in the prior art, and the intestinal inflammation symptom of freshwater fish caused by high-fat feed can be remarkably relieved by adding mannooligosaccharide into the high-fat feed, optimizing and improving various components and the feed prepared by using the same.
In order to achieve the above object, the present invention provides the following solutions:
the invention provides an application of mannooligosaccharide in preparing feed for reducing intestinal inflammation of freshwater fish caused by high-fat feed.
Preferably, the freshwater fish comprises a carnivorous freshwater fish.
Preferably, the carnivorous freshwater fish includes, but is not limited to, siniperca chuatsi, micropterus salmoides, or snakeheads.
The invention also provides a high-fat feed containing the mannooligosaccharide, which comprises the following components in parts by weight: 600-800 parts of fish meal, 50-100 parts of casein, 30-120 parts of fish oil, 50-120 parts of corn starch, 30-40 parts of microcrystalline cellulose, 15-25 parts of multivitamin premix, 25-35 parts of sodium carboxymethyl cellulose and 3-8 parts of mannooligosaccharide.
Preferably, the composition comprises the following components in parts by weight: 600 parts of fish meal, 70 parts of casein, 120 parts of fish oil, 100 parts of corn starch, 35 parts of microcrystalline cellulose, 20 parts of multivitamin premix, 30 parts of sodium carboxymethyl cellulose and 5 parts of mannooligosaccharide.
Preferably, the multivitamin premix comprises the following components in parts by weight: 10 parts of vitamin A, 16 parts of vitamin B, 25 parts of vitamin B, 67.5 parts of vitamin B, 124 parts of vitamin B, 50 parts of nicotinamide, 500 parts of calcium ascorbyl phosphate, 20 parts of calcium pantothenate, 2.5 parts of biotin, 5 parts of folic acid, 200 parts of vitamin E, 310 parts of vitamin K, 350 parts of vitamin D, 100 parts of inositol and 75 parts of corn gluten meal.
Preferably, the premix of the multiple minerals comprises the following components in parts by weight: 10 parts of cupric sulfate pentahydrate, 300 parts of ferrous sulfate monohydrate, 200 parts of zinc sulfate monohydrate, 100 parts of manganese sulfate monohydrate, 80 parts of potassium iodate, 67 parts of sodium selenite, 5 parts of cobalt chloride hexahydrate, 100 parts of sodium chloride and 638 parts of zeolite.
The invention discloses the following technical effects:
The mannooligosaccharide disclosed by the invention is applied to reducing the intestinal inflammation of freshwater fish caused by high-fat feed, and the mannooligosaccharide reduces the intestinal inflammation of freshwater fish caused by high-fat feed by regulating the expression of related genes of pro-inflammatory cytokines, anti-inflammatory cytokines and intestinal barriers of the intestinal tract and liver. The action mechanism is as follows: the high-fat feed obviously up-regulates the gene expression quantity of freshwater fish intestinal nf- κb, pro-inflammatory cytokines il-1 beta, il-8 and tgf β, and obviously down-regulates the expression quantity of intestinal barrier related genes jam2α, and the application of the high-fat feed containing mannooligosaccharide obtained through the optimization and adjustment of components and dosage obviously increases the expression quantity of anti-inflammatory cytokines il-10 and intestinal barrier related genes occludin, and obviously reduces the gene expression quantity of pro-inflammatory cytokines il-1 beta, il-8 and tgf beta. In addition, the expression level of the liver pro-inflammatory cytokine il-8 of the freshwater fish which ingests the high-fat feed is obviously increased, and the expression level of the anti-inflammatory cytokine tgf beta is obviously reduced; after the high-fat feed containing the mannooligosaccharide is taken, the expression level of liver anti-inflammatory cytokines nf- κb, il-lβ and tgf β is obviously increased, and the expression level of pro-inflammatory cytokine il-8 is obviously reduced, so that the intestinal inflammation of freshwater fish caused by the high-fat feed is reduced.
The invention also discloses a feed for reducing the intestinal inflammation of the freshwater fish caused by the high-fat feed, namely the high-fat feed containing the mannooligosaccharide, and the intestinal inflammation of the freshwater fish caused by the high-fat feed is reduced by adding the mannooligosaccharide into the high-fat feed, optimizing and improving various components and the dosage of the high-fat feed so as to regulate the expression of proinflammatory cytokines and anti-inflammatory cytokines. The high-fat feed containing the mannooligosaccharide provided by the invention can obviously relieve the intestinal inflammation of the freshwater fish caused by the conventional high-fat feed, has important significance for improving the intestinal inflammation of the freshwater fish and culturing the freshwater fish, and also provides a novel high-fat feed formula.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 shows microscopic observation results of intestinal HE staining of freshwater fish of different groups according to the invention; * P <0.05 represents significant differences, data are expressed as mean ± standard error (n=6); GC: goblet cell, goblet cells; EG: eosinophilic granulocyte eosinophils; LP: lamina pria, lamina propria; MC: muscular thickness, muscular layer thickness; MF: mucosalfold, intestinal mucosa fold; VL: villus length, fluff length;
FIG. 2 shows the results of detecting the relative expression levels of intestinal barrier genes of different groups of freshwater fish according to the present invention; * P <0.05 represents significant differences, data are expressed as mean ± standard error (n=9); jam2α: ligating adhesion molecule 2α; occludin: a closure protein; zo1: cytoplasmic compact adhesive protein-1; claudin: a tight junction protein;
FIG. 3 shows the results of detecting the relative expression levels of intestinal inflammatory genes of different groups of freshwater fish according to the present invention; * P <0.05 represents significant differences, data are expressed as mean ± standard error (n=9); nf- κb: nuclear transcription factors; il-1 beta: interleukin 1 beta; il-8: interleukin 8; il-10: interleukin 10; tgf beta: transforming growth factor beta;
FIG. 4 shows the results of detecting the relative expression levels of liver inflammatory genes of different groups of freshwater fish according to the present invention; * P <0.05 represents significant differences, data are expressed as mean ± standard error (n=9); nf- κb: nuclear transcription factors; il-1 beta: interleukin 1 beta; il-8: interleukin 8; il-10: interleukin 10; tgf beta: transforming growth factor beta.
Detailed Description
Various exemplary embodiments of the invention will now be described in detail, which should not be considered as limiting the invention, but rather as more detailed descriptions of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. In addition, for numerical ranges in this disclosure, it is understood that each intermediate value between the upper and lower limits of the ranges is also specifically disclosed. Every smaller range between any stated value or stated range, and any other stated value or intermediate value within the stated range, is also encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the invention described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from consideration of the specification of the present invention. The specification and examples of the present invention are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are intended to be inclusive and mean an inclusion, but not limited to.
Example 1
1. Experimental method
1.1 Preparation of feed
Control group feed: the specific formula and chemical composition of the basic fish feed are shown in Table 1.
Mannooligosaccharide group feed: the mannooligosaccharide (the addition ratio of the mannooligosaccharide to the total amount of the fish feed is 5g:1 kg) is added into the basic fish feed.
High-fat group feed: fish oil is added into the basic fish feed (the adding ratio of the fish oil to the total amount of the fish feed is 120 g/1 kg).
High fat + mannooligosaccharide group feed: fish oil and mannooligosaccharide (the addition ratio of the fish oil, the mannooligosaccharide and the total amount of the fish feed is 120g:5g:1 kg) are added into the basic fish feed.
The feed ingredients were thoroughly mixed and granulated, and the pellets were dried in an oven at 50 ℃ and stored at 4 ℃.
Table 1 shows the formulation and chemical composition of each group of feeds
Multidimensional premix mainly containing multiple vitamins; polymineral is a premix containing mainly multiple minerals.
Of the above feeds, 20g of multidimensional/kg feed: vitamin a,10g; vitamin B1,6g; vitamin B2,5g; vitamin B6,7.5g; vitamin B12 (1%), 4g; nicotinamide (C 6H6N2 O), 50g; calcium ascorbyl phosphate (C 18H24Ca3O26P2, 35%), 500g; calcium pantothenate (CHCaN 2 O), 20g; biotin (C 10H16N2O3 S, 2%), 2.5g; folic acid, 5g; vitamin E (50%), 200g; vitamin K3, 10g; vitamin D3, 50g; inositol (C 6H12O6), 100g; corn gluten meal, 75g.
Mineral premix, 20g polymineral/kg feed: copper sulfate pentahydrate (CuSO 4·5H2 O), 10g; ferrous sulfate monohydrate (FeSO 4·H2 O), 300g; zinc sulfate monohydrate (ZnSO 4·H2 O), 200g; manganese sulfate monohydrate (MnSO 4·H2 O), 100g; potassium iodate (KIO 3, 10%), 80g; sodium selenite (Na 2SeO3,, 10% se), 67g; cobalt chloride hexahydrate (CoCl 2·6H2 O,10% co), 5g; sodium chloride (NaCl), 100g; zeolite 638g.
In the feed components, the percentage in brackets is the mass content.
1.2 Laboratory animals and feeding trials
In the embodiment of the invention, siniperca chuatsi is selected as experimental fish.
All fish were acclimatized to the control diet in the indoor recirculating aquaculture system for two weeks prior to the experiment. Healthy fish (initial body weight: 21.18±0.01 g) of the same size were then randomly distributed into indoor circulating aquaculture drums (25 tail per drum, r=0.4 m, h=1 m) and divided into control group, mannooligosaccharide group, high fat group and high fat+mannooligosaccharide group, and three parallel treatments were set for each group.
The control group, the mannooligosaccharide group, the high-fat group and the high-fat and mannooligosaccharide group feed were used for feeding at 8:30 and 16:00 each day, and the culture experiment was continued for 5 weeks. The water temperature is kept at 29.5-32.2 ℃; the pH value is 7.4-8.1; the dissolved oxygen is 3.2-4.1 mg.L -1, and the total ammonia nitrogen is less than 0.2 mg.L -1.
1.3 Sample collection
At the end of the experiment, blood was collected from the tail vein of each barrel of three tail fish using a syringe infiltrated with 0.2% heparin sodium solution. Plasma was obtained by centrifugation at 3000g for 10min at 4 ℃ and was rapidly transferred to-80 ℃ for storage for further analysis. Under ice bath conditions, liver tissue was rapidly taken, snap frozen in liquid nitrogen and then transferred to-80 ℃ for subsequent gene expression analysis, and a small piece of intestinal tract was fixed in 4% paraformaldehyde for histological analysis.
1.4 Real time quantitative polymerase chain reaction (qRT-PCR)
Total RNA was extracted from the intestinal tract and liver. qRT-PCR was used to detect relevant indicators, including key genes involved in inflammation and intestinal barrier, using 18S rRNA and rpl13α as housekeeping genes, respectively.
1.5 Statistical analysis
The single factor analysis of variance comparison was performed on the CON, MOS, HF and hf+mos groups using SPSS19.0 software, with P <0.05 (x) being significant difference. All results are expressed as mean ± standard error (n=9).
2. Results and analysis
2.1 Intestinal HE stained sections
As shown in fig. 1, the microstructure of the mandarin fish intestinal canal HE dyed slice is observed, and the influence of the addition of the mannooligosaccharide to the mandarin fish intestinal canal structure is detected. The research result shows that the length of the intestinal villus and the thickness of the muscle layer of the siniperca chuatsi in the HF group are obviously reduced, and the HF+MOS group added with the mannooligosaccharide in the high-fat feed has no obvious difference with the HF group.
2.2 Intestinal Barrier Gene expression
As shown in FIG. 2, the relative expression levels of intestinal barrier genes of different groups of freshwater fish are detected to evaluate the influence of the addition of mannooligosaccharides to the expression level of the intestinal barrier genes of siniperca chuatsi in high-fat feed. The research result shows that the gene expression level of the siniperca chuatsi intestinal jama is obviously lower than that of the CON group, and the HF+MOS group of the high-fat feed mannose oligosaccharide obviously increases the gene expression level of the siniperca chuatsi intestinal occludin. The expression level of the siniperca chuatsi intestinal zol and claudin genes in the HF group is not significantly different from that in the control group, and the HF+MOS group added with the mannooligosaccharide in the high-fat feed is also not significantly different from that in the HF group.
2.3 Intestinal inflammation Gene expression
As shown in FIG. 3, the relative expression levels of intestinal inflammation genes of different groups of freshwater fish are detected to evaluate the influence of the addition of mannooligosaccharides to the expression levels of intestinal inflammation genes of siniperca chuatsi in high-fat feed. The research result shows that compared with the CON group, the expression levels of the siniperca chuatsi intestinal tracts nf- κb, il-1 beta, il-8 and tgf beta in the HF group are obviously up-regulated; compared with the HF group, the expression level of the mandarin intestinal tracts il-1 beta, il-8 and tgf beta in the HF+MOS group is obviously down-regulated, and the expression level of the il-10 is obviously up-regulated.
2.4 Liver inflammation Gene expression
As shown in FIG. 4, the relative expression levels of liver inflammation genes of different groups of freshwater fish are detected to evaluate the influence of the addition of mannooligosaccharides to the expression levels of liver inflammation genes of siniperca chuatsi in high-fat feed. Research results show that compared with CON group, the expression level of siniperca chuatsi intestinal tracts nf- κb and tgf β in HF group is obviously down-regulated, and the expression level of il-8 is obviously up-regulated; compared with the HF group, the expression level of siniperca chuatsi intestinal tracts nf- κb, il-1 beta and tgf beta in the HF+MOS group is obviously up-regulated, and the expression level of il-8 is obviously down-regulated.
From the above experimental results, it can be seen that the high-fat feed significantly up-regulates the gene expression levels of the freshwater fish intestinal nf- κb, the pro-inflammatory cytokines il-1 β, il-8 and tgf β and significantly down-regulates the expression level of the intestinal barrier related gene jam2α, whereas the addition of mannooligosaccharides to the high-fat feed significantly increases the expression levels of the anti-inflammatory cytokines il-10 and the intestinal barrier related gene occludin and significantly reduces the gene expression levels of the pro-inflammatory cytokines il-1 β and il-8. In addition, the expression level of the freshwater fish liver pro-inflammatory cytokine il-8 which is ingested with the high-fat feed is obviously increased, and the expression level of the anti-inflammatory cytokine tgf beta is obviously reduced; after the fish which ingests the high-fat feed containing the mannooligosaccharide, the expression level of the liver anti-inflammatory cytokine tgf β is obviously increased, and the expression level of the pro-inflammatory cytokine il-8 is obviously reduced, so that the intestinal inflammation of the freshwater fish caused by the high-fat feed is reduced.
In the present invention, the amount of mannooligosaccharide to be added may be adjusted according to the actual situation, and is not limited to the ratio of the above-described examples, and the intestinal inflammation of freshwater fish can be reduced by controlling the expression of pro-inflammatory cytokines and anti-inflammatory cytokines.
It will be appreciated by those skilled in the art that the present invention may also employ mannooligosaccharides for use in the alleviation of other species of freshwater carnivorous fish, for example: intestinal inflammation of carnivorous fish such as largemouth black bass and snakehead under high-fat feed.
In summary, the invention provides application of the mannooligosaccharide in reducing intestinal inflammation of freshwater fish caused by high-fat feed. The high-fat feed remarkably promotes the gene expression quantity of freshwater fish intestinal nf- κb, pro-inflammatory cytokines il-1 beta, il-8 and tgf beta, and remarkably inhibits the expression quantity of intestinal barrier related gene jam2 alpha; the expression level of anti-inflammatory cytokines il-10 and intestinal barrier related gene occludin is obviously increased by the application of the high-fat feed containing the mannooligosaccharide, and the gene expression level of pro-inflammatory cytokines il-1 beta, il-8 and tgf beta is obviously reduced. In addition, the expression level of the liver pro-inflammatory cytokine il-1 beta of the freshwater fish which ingests the high-fat feed is obviously up-regulated, and the expression level of the anti-inflammatory cytokine tgf beta is obviously down-regulated; after the high-fat feed containing the mannooligosaccharide is taken, the expression levels of liver anti-inflammatory cytokines nf- κb, il-lβ and tgf β are obviously up-regulated, and the expression level of pro-inflammatory cytokine il-8 is obviously down-regulated, so that the intestinal inflammation of freshwater fish caused by the high-fat feed is reduced. The invention also provides a feed for reducing the intestinal inflammation of the freshwater fish caused by the high-fat feed, which comprises basic fish feed, fish oil and mannooligosaccharide for reducing the intestinal inflammation of the freshwater fish caused by the high-fat feed; the feed can reduce the intestinal inflammation of freshwater fish by adjusting pro-inflammatory cytokines and anti-inflammatory cytokines through the addition of the mannooligosaccharide and the optimization and improvement of each component, and has important significance for improving the intestinal inflammation of freshwater fish caused by high-fat feed.
The above embodiments are only illustrative of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention, and various modifications and improvements made by those skilled in the art to the technical solutions of the present invention should fall within the protection scope defined by the claims of the present invention without departing from the design spirit of the present invention.
Claims (7)
1. The application of mannooligosaccharide in preparing feed for relieving intestinal inflammation of freshwater fish caused by high-fat feed is provided.
2. The use of claim 1, wherein the freshwater fish comprises a carnivorous freshwater fish.
3. The use of claim 2, wherein the carnivorous freshwater fish comprises siniperca chuatsi, larch, or snakehead.
4. The high-fat feed containing the mannooligosaccharides is characterized by comprising the following components in parts by weight: 600-800 parts of fish meal, 50-100 parts of casein, 30-120 parts of fish oil, 50-120 parts of corn starch, 30-40 parts of microcrystalline cellulose, 15-25 parts of multivitamin premix, 25-35 parts of sodium carboxymethyl cellulose and 3-8 parts of mannooligosaccharide.
5. The high-fat diet containing mannooligosaccharide of claim 4, comprising the following components in parts by weight: 600 parts of fish meal, 70 parts of casein, 120 parts of fish oil, 100 parts of corn starch, 35 parts of microcrystalline cellulose, 20 parts of multivitamin premix, 30 parts of sodium carboxymethyl cellulose and 5 parts of mannooligosaccharide.
6. The high-fat diet containing mannooligosaccharide according to claim 4 or 5, wherein the multivitamin premix comprises the following components in parts by weight: 10 parts of vitamin A, 16 parts of vitamin B, 25 parts of vitamin B, 67.5 parts of vitamin B, 124 parts of vitamin B, 50 parts of nicotinamide, 500 parts of calcium ascorbyl phosphate, 20 parts of calcium pantothenate, 2.5 parts of biotin, 5 parts of folic acid, 200 parts of vitamin E, 310 parts of vitamin K, 350 parts of vitamin D, 100 parts of inositol and 75 parts of corn gluten meal.
7. The high-fat diet containing mannooligosaccharide according to claim 4 or 5, wherein the premix of the plurality of minerals comprises the following components in parts by weight: 10 parts of cupric sulfate pentahydrate, 300 parts of ferrous sulfate monohydrate, 200 parts of zinc sulfate monohydrate, 100 parts of manganese sulfate monohydrate, 80 parts of potassium iodate, 67 parts of sodium selenite, 5 parts of cobalt chloride hexahydrate, 100 parts of sodium chloride and 638 parts of zeolite.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410277618.6A CN117941777A (en) | 2024-03-12 | 2024-03-12 | Application of mannooligosaccharide in preparation of feed for reducing intestinal inflammation of freshwater fish caused by high-fat feed |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410277618.6A CN117941777A (en) | 2024-03-12 | 2024-03-12 | Application of mannooligosaccharide in preparation of feed for reducing intestinal inflammation of freshwater fish caused by high-fat feed |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117941777A true CN117941777A (en) | 2024-04-30 |
Family
ID=90796479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410277618.6A Pending CN117941777A (en) | 2024-03-12 | 2024-03-12 | Application of mannooligosaccharide in preparation of feed for reducing intestinal inflammation of freshwater fish caused by high-fat feed |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117941777A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1615727A (en) * | 2003-11-13 | 2005-05-18 | 中国科学院微生物研究所 | Oligose fodder additive and its producing method |
| WO2008051091A1 (en) * | 2006-10-25 | 2008-05-02 | Ewos Innovation As | Fish feed and uses thereof |
| CN102783566A (en) * | 2012-08-24 | 2012-11-21 | 无锡华诺威动物保健品有限公司 | Feed premix with intestine prompting function for aquatic livestock and preparation method for feed premix |
| CN107811128A (en) * | 2017-11-13 | 2018-03-20 | 赣州播恩生物技术股份有限公司 | A kind of feed addictive of adjustable intestine of young pigs flora |
| CN109105665A (en) * | 2018-09-05 | 2019-01-01 | 山东大学 | A kind of protectant method of screening turbot feed |
| CN109331028A (en) * | 2018-10-15 | 2019-02-15 | 山东大学 | A kind of trophism prophylactic of turbot enteritis disease |
| CN109811022A (en) * | 2019-03-28 | 2019-05-28 | 南京益纤生物科技有限公司 | A kind of preparation method and applications of galactomannan-oligosaccharide |
| CN111990554A (en) * | 2020-07-20 | 2020-11-27 | 中国水产科学研究院南海水产研究所 | High-fat feed formula for deep-sea cage cultured fish and preparation method thereof |
-
2024
- 2024-03-12 CN CN202410277618.6A patent/CN117941777A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1615727A (en) * | 2003-11-13 | 2005-05-18 | 中国科学院微生物研究所 | Oligose fodder additive and its producing method |
| WO2008051091A1 (en) * | 2006-10-25 | 2008-05-02 | Ewos Innovation As | Fish feed and uses thereof |
| CN102783566A (en) * | 2012-08-24 | 2012-11-21 | 无锡华诺威动物保健品有限公司 | Feed premix with intestine prompting function for aquatic livestock and preparation method for feed premix |
| CN107811128A (en) * | 2017-11-13 | 2018-03-20 | 赣州播恩生物技术股份有限公司 | A kind of feed addictive of adjustable intestine of young pigs flora |
| CN109105665A (en) * | 2018-09-05 | 2019-01-01 | 山东大学 | A kind of protectant method of screening turbot feed |
| CN109331028A (en) * | 2018-10-15 | 2019-02-15 | 山东大学 | A kind of trophism prophylactic of turbot enteritis disease |
| CN109811022A (en) * | 2019-03-28 | 2019-05-28 | 南京益纤生物科技有限公司 | A kind of preparation method and applications of galactomannan-oligosaccharide |
| CN111990554A (en) * | 2020-07-20 | 2020-11-27 | 中国水产科学研究院南海水产研究所 | High-fat feed formula for deep-sea cage cultured fish and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 夏青等: "功能性寡糖调控肠道健康的研究进展", 《食品工业科技》, vol. 42, no. 21, 30 November 2021 (2021-11-30), pages 428 - 434 * |
| 宋青春: "《水产动物营养与配合饲料学》", 30 June 2019, 中国农业大学出版社, pages: 70 * |
| 翟浩杰等: "甘露寡糖对养殖鱼类生长性能和非特异性免疫的研究进展", 《安徽农业科学》, vol. 49, no. 23, 31 December 2021 (2021-12-31), pages 17 - 21 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yuan et al. | Effects of xylo-oligosaccharide and flavomycin on the immune function of broiler chickens | |
| Wang et al. | Nutrient digestibility, blood profiles and fecal microbiota are influenced by chitooligosaccharide supplementation of growing pigs | |
| Liu et al. | Resveratrol inclusion alleviated high-dietary-carbohydrate-induced glycogen deposition and immune response of largemouth bass, Micropterus salmoides | |
| JP6514291B2 (en) | Dietary intervention improves gastrointestinal health, immunity and function | |
| Zhao et al. | Short-chain fructo-oligosaccharides enhances intestinal barrier function by attenuating mucosa inflammation and altering colonic microbiota composition of weaning piglets | |
| ZA200604542B (en) | Anti-diarrhea composition containing glutamine | |
| Löest et al. | Soybean hulls as a primary ingredient in forage-free diets for limit-fed growing cattle | |
| Bai et al. | High dietary energy content increases inflammatory markers after lipopolysaccharide challenge in meat ducks | |
| Yin et al. | Dietary high protein-induced diarrhea and intestinal inflammation by activation of NF-κB signaling in piglets | |
| Zhou et al. | Different dietary starch patterns in low-protein diets: effect on nitrogen efficiency, nutrient metabolism, and intestinal flora in growing pigs | |
| Wang et al. | Effects of varying dietary folic acid during weaning stress of piglets | |
| Zhong et al. | Sodium butyrate promotes gastrointestinal development of preweaning bull calves via inhibiting inflammation, balancing nutrient metabolism, and optimizing microbial community functions | |
| Xu et al. | Dietary phosphorus deficiency impaired growth, intestinal digestion and absorption function of meat ducks | |
| CN117941777A (en) | Application of mannooligosaccharide in preparation of feed for reducing intestinal inflammation of freshwater fish caused by high-fat feed | |
| CN116649508A (en) | Composite procambarus clarkia feed, preparation method and application | |
| CN118141018A (en) | Application of chitosan oligosaccharide in preparation of feed for reducing intestinal inflammation of freshwater fish caused by high-fat feed | |
| WO2022068273A1 (en) | Bacillus coagulans having blood glucose reduction efficacy, and application thereof | |
| Liu et al. | The Growth Rate, Immune Status, Duodenal Development, and Cecal Microbial Diversity of 24-Day-Old Offspring of SD Rats Received Bacillus subtilis-Cu or CuSO 4 During Pregnancy and Lactation Periods | |
| CN108060098B (en) | Fermentation culture method of escherichia coli and application of escherichia coli in feed additive | |
| Li et al. | Effect of Low Protein Diets Supplemented with Sodium Butyrate, Medium-Chain Fatty Acids, or n-3 Polyunsaturated Fatty Acids on the Growth Performance, Immune Function, and Microbiome of Weaned Piglets | |
| Demarco et al. | Effects of bacterial DFM and tannins on measures of immunity and growth performance of newly weaned beef calves | |
| Wang et al. | Effects of supplemental Glycyrrhiza polysaccharide on growth performance and intestinal health in weaned piglets | |
| Huang et al. | Effects of Bacillus Subtilis-Zinc on Rats with Congenital Zinc Deficiency | |
| CN116982672B (en) | Application of betaine in improving ingestion and sugar utilization of siniperca chuatsi high-sugar feed | |
| Cai et al. | Growth performance, nutrient digestibility, blood profile, gut health and La deposition of weaning rabbits fed with a low dosage of La2O3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |